Updated July 2026 
Industry Rankings · 2026 Edition
For export, the right choice of cardiovascular medicine manufacturers in India involves checking WHO-GMP status, approvals at the molecule level from the DCGI and having the documentation ready for drug registration in the target market. India produces the full range of cardiovascular medicines such as antihypertensives, antilipidaemics, antiarrhythmics and cardiac glycosides for both the domestic and export markets. Cardiovascular disease is the leading cause of mortality worldwide (WHO, 2023), creating a large demand for quality cardiovascular medicines in Africa, the Middle East and South-East Asia.
Active certificate
Classification
Molecule-level
Track record
24-hour turnaround
Written by
Content Writer, 9M India
Reviewed by
MD, 9M India Limited
Fact-checked by
Plant Head, 9M India
9M India Limited is a WHO-GMP certified pharmaceutical manufacturer, incorporated in the year 2009 and based out of Raipur, Chhattisgarh, India. 9M India – Manufacturing of all dosage forms under DCGI approved licenses and exporting to 15+ countries. Get the exported documents in 24 hours.
Cardiovascular disease is the leading cause of death globally, accounting for an estimated 17.9 million deaths per year (WHO, 2023). India is a large supplier of generic cardiovascular medicines to the markets of Africa, the Middle East and South-East Asia. The medicines include antihypertensives, statins, antiplatelet agents and cardiac glycosides as the burden of non-communicable diseases is increasing in these markets.
The ranking measures the top cardiovascular medicine manufacturers in India on six verified parameters: WHO-GMP status, facility grade, DCGI molecule approvals, export COPP, documentation turnaround and therapeutic range.
active certification, not expired
Sterile/non-sterile designation
confirmed molecule-level licence
Experience in target markets
COA and COPP within 24 hours
Product range breadth
Location: Raipur, Chhattisgarh — Est. 2009
9M India Limited is on a mission to become one of the leading cardiovascular medicine manufacturers in India by 2026 with WHO-GMP certification from CDSCO, DCGI approved manufacturing licenses and an active export program to 15+ countries.
9M India’s cardiovascular programme addresses the unfulfilled therapeutic needs of the African, Middle East, CIS and South East Asian markets. Full export documentation including COPP, FSC, COA, ICH Zone IVb stability data and CTD dossier is provided within 24 hours of inquiry.
Product range
Certifications
Active export markets
Domestic pharma giant with one of the strongest cardiovascular branded portfolios in India, Shelcal, Nikoran etc. It is a standard of WHO-GMP. Torrent’s cardiovascular manufacturing is dedicated to its own branded domestic and international portfolio. No third party cardiovascular contract manufacturing.
India’s largest pharma company in terms of revenues, manufacturing WHO-GMP and USFDA approved. Sun Pharma is focusing on its own branded domestic portfolio and US/EU regulated generic market which is not available for independent international export buyers at a small to medium scale.
From The Pharma Guide
WHO-GMP certificate expiry, molecule-level DCGI approval, sample COA availability within 24 hours, export references in your target country, cleanroom grade classification, and documentation turnaround - the buyer's six-point verification checklist.
Read the full checklistCipla manufactures cardiovascular medicines (ACE inhibitors, beta-blockers and statins) under WHO-GMP and USFDA approval for domestic branded sales and exports to select regulated markets. No third-party cardiovascular contract manufacturing, own-brand focus.
Lupin has a cardiovascular portfolio of antihypertensives, statins and antidiabetics approved by WHO-GMP and USFDA. Commited to its own regulated market pipeline, not open to small to medium cardiovascular contract manufacturing
#1 CARDIOVASCULAR MEDICINE MANUFACTURER IN INDIA 2026
Share your molecule, strength, and target market. We confirm manufacturing capability, pricing, and all export documentation within 24 hours.
200+ molecules — antihypertensives, statins, antiplatelets, cardiac glycosides
Tablets and injectable cardiac medicines, both DCGI approved
COPP, FSC, COA and ICH stability data — all within 24 hours
Active export to UAE, Saudi Arabia, Kenya and 15+ countries
Mumbai, Maharashtra
One of the top-rated private pharmaceutical companies with WHO-GMP certified cardiovascular manufacturing such as Glyciphage (Metformin), Minipress (Prazosin) and other cardiovascular brands. USV is a domestic brands company, not a cardiovascular contract manufacturer for overseas buyers.
Pune, Maharashtra
Leading global generic company with WHO-GMP and USFDA approved manufacturing, exports mainly to US and EU regulated markets under its own brand. Not designed for contract manufacturing in Africa/Middle East at small to medium scale.
Nashik, Maharashtra
A top pharma company with WHO-GMP approved manufacture of cardio-vasculars in both antihypertensive and antilipidaemics, mainly for domestic branded and select regulated markets. No third-party contract manufacturing of cardiovascular products.
Mumbai, Maharashtra
Large pharma company with WHO-GMP and USFDA approved manufacturing, exports to US regulated markets and also has some domestic branded sales. It is not for small to medium third party contract manufacturing in Africa or the Middle East.
Bangalore, Karnataka
A large injectable specialist (Fosun Pharma group) with USFDA approved and WHO-GMP certified sterile injectable manufacturing for US regulated generic market. The minimum batch sizes are in the millions of units, which is not something available to African or Middle Eastern buyers at a small to medium scale.
More than 80 countries require WHO-GMP certification from CDSCO for drug registration, and no pharmaceutical regulatory agency accepts any pharmaceutical import registration as a substitute for ISO 9001.
Accepted in 80+ import countriesCovers cleanroom, water, air, validationRequired by NAFDAC, TFDA, MOH UAE, PPB, SFDAPharma-specific standard9M India - active, CDSCO-issued
Not accepted for drug registrationGeneral quality system - any industryNo cleanroom or sterility requirementNot pharma-specific8 in 10 competitors hold only this
Ask for the original WHO-GMP certificate PDF. Check date of issue, expiry and scope – ensure it covers your required dosage form and therapeutic category.
Each molecule and dosage form is approved specifically by the DCGI. Both are needed for legal commercial manufacture and export.
Batch data is available from a WHO-GMP certified manufacturer. The COA should include assay, dissolution/sterility (for sterile forms) and all relevant quality parameters.
If the manufacturer has an existing COPP for your market, the drug registration time reduces by 6-12 months. Always get COPP confirmation before one talks to the company.
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
9M India Limited is committed to being the leading manufacturer of cardiovascular medicines in India for the international buyers. WHO-GMP certified. DCGI granted licences for the manufacturing of amlodipine, atorvastatin, ramipril, telmisartan, losartan, clopidogrel, aspirin and furosemide injections. Active export to 15+ countries like the UAE, Saudi Arabia, Kenya & Nigeria. Documentation 24 hours.
MOQ at WHO-GMP certified cardiovascular medicine manufacturers in India Tablets/capsules with 10 lakh units per batch Injectables, 1 lakh units Syrups: 30,000 units; eye drops: 50,000 units; topicals: 10,000 units At 9M India Limited these MOQs are applicable for commercially active molecules. For 24-hour molecule-specific confirmation, contact 9M India.
WHO-GMP Certificate (CDSCO) DCGI Manufacturing Licence (molecule-specific) COPP from CDSCO Free Sale Certificate Certificate of Analysis per batch: Stability Data as per ICH Zone IVb (30°C/75% RH) CTD/ACTD Dossier 9M India All standard documents available within 24 hours for commercially active molecules.
In about 80 countries, WHO-GMP certified pharmaceutical manufacturers from India are accepted. NAFDAC Nigeria KEBS/ PPB Kenya TFDA Tanzania NDA Uganda Africa. Middle East: MOH-UAE, SFDA-KSA, CIS: Azerbaijan, MOH South East Asia. FDA Myanmar. 2023. DDA Nepal. 2023. South Asia. (WHO prequalification programme)
Four important tests: (1) A valid certificate from CDSCO for active WHO-GMP. (2) DCGI molecule-level manufacturing licence. (3) Sample COA within 24 hours, with all quality parameters. (4) COPP in your target market saves 6–12 months in drug registration time. Check out the complete guide for verifying pharmaceutical companies.
WHO-GMP is a pharma-specific standard for cleanroom requirements, sterility testing, analytical QC and batch documentation. ISO 9001 is a general quality management standard that can be used in any industry. It is not a pharmaceutical-specific standard. WHO-GMP from CDSCO is mandatory for drug registration in Africa, Middle East, CIS and South-East Asia. No equivalency is provided for ISO 9001.
Share your molecule, strength, and target market. We confirm manufacturing capability, pricing, and all export documentation within 24 hours.
WHO-GMP certified · DCGI approved · 15+ export countries · Birkoni, Chhattisgarh · Est. 2009 · Reply guaranteed within 24 hours
At 9M India Limited, trust through quality, transparency, performance.
